HPV Vaccine's 'Extraordinary Benefits' Seen in Cochrane Review

Maurie Markman, MD


June 07, 2018

Hello. I'm Dr Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss an extremely important report just published by the Cochrane Library, a group responsible for high-quality meta-analyses on health-related issues. This article, "Prophylactic Vaccination Against Human Papillomaviruses to Prevent Cervical Cancer and Its Precursors,"[1] demonstrates once again the extraordinary benefits and safety associated with human papillomavirus (HPV) vaccination.

The analysis looked at results of 26 phase 3 trials involving more than 73,000 participants. These were randomized, blinded trials that looked at placebo controls, with follow-ups as long as 8 years. The study demonstrated the extraordinary effectiveness—almost to the point of 100%—in preventing high-grade cervical intraepithelial neoplasia (CIN) grade 3 cervical lesions in young women who had not previously had evidence of HPV persistent infections—basically, before these young women had the opportunity to be exposed to HPV through sexual transmission.

In addition, in this very large database there was no difference in the incidence of side effects observed and no evidence for increased risk for miscarriage.

Of course, we've had these data for a long time. This compilation of large high-quality studies with long-term follow-up once again emphasizes the very major benefits associated with HPV vaccination and the potential substantial reduction in cervix cancer.

I encourage all individuals involved in public health matters, oncologists, gynecologists, pediatricians, and parents of young girls to see, review, and understand this report. Obviously, HPV vaccination is relevant for boys, but in this case we're talking about cervix cancer. This is an extremely important public health measure. I thank you for your attention.